We hypothesised that CYP2B6 slow metabolisers treated with efavirenz and isoniazid will have increased efavirenz concentrations with an increased risk of efavirenz-related neurotoxicity, hepatotoxicity, dyslipidaemia, and dysglycaemia. Here, CYP2B6 is linked to inherited lipid metabolism disorder.